| Description | Retelliptine, a DNA topoisomerase II inhibitor, is used potentially for the treatment of cancer. |
| Synonyms | SR-95325B (diHCl), NSC-D-626717-W, SR-95325A (dimaleate), BD-84 |
| molecular weight | 404.55 |
| Molecular formula | C25H32N4O |
| CAS | 72238-02-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP, Azab M. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. Am J Clin Oncol. 1994 Jun;17(3):242-5. PubMed PMID: 8192111. 2. Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, Fiebig HH, Boven E. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol. 1994 May;5(5):415-22. PubMed PMID: 8075048. 3. Maulard C, Urien S, Bastian G, Tillement JP. Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes. Biochem Pharmacol. 1990 Aug 15;40(4):895-8. PubMed PMID: 2386553. 4. Ono K, Nakane H, Barre-Sinoussi F, Chermann JC. Differential inhibition by an antitumoral drug 10-[gamma-diethylaminopropylamino]-6-methyl-5H-pyrido[3',4': 4,5]pyrrolo [2,3-G]isoquinoline (BD-40), a pyrido-pyrrolo-isoquinoline derivative, of in vitro DNA synthesis catalyzed by various DNA polymerases. Cancer Lett. 1990 May 15;51(1):59-65. PubMed PMID: 1692511. |